Oncology Newsfeed

CMS to Host 2017 MIPS Submission Q & A Sessions

The Centers for Medicare & Medicaid Services (CMS) is hosting three “Office Hours” sessions on Merit-based Incentive Payment Systems (MIPS) submission over the next several weeks. CMS subject matter experts will answer commonly asked questions about the submission feature on qpp.cms.gov, and answer attendees’ questions live. Registrants will also be able to submit questions by email prior to the sessions.

View “Office Hours” topics and register below. Please note that Qualified Registries, Qualified Clinical Data Registries and Web Interface Reporters should use their support calls for data submission support.

February 14, 3:30-4:30 pm ET

Quality Payment Program Data Submission Office Hours: Individual Eligible Clinician and Group Submission

Register

February 28, 3-4 pm ET

Quality Payment Program Data Submission Office Hours: MIPS Quality Data Submission

Register

March 14, 3-4 pm ET

Quality Payment Program Data Submission Office Hours: MIPS Attestation for Advancing Care Information and Improvement Activities

Register

Space for these sessions is limited. Register now to secure your spot. The audio portion of the sessions will be broadcast through the web. You can listen to the presentation through your computer speakers.

For More Information

For step-by-step instructions on how to submit MIPS data, check out this video and fact sheet. Questions about your participation status or MIPS data submission? Contact the Quality Payment Program Service Center by
email: qpp@cms.hhs.gov.

Posted on 2/19/2018

MIPS Reporting Deadlines Coming Soon

Planning to submit data for the 2017 Merit-based Incentive Payment System (MIPS) Merit-based Incentive Payment System (MIPS) performance period? Deadlines are coming in March, and the Centers for Medicare & Medicaid Services (CMS) urges providers not to wait until the last minute to submit data.

The two key dates are:

• March 16 at 8 pm ET for group reporting via the CMS web interface
• March 31 for all other MIPS reporting, including via qpp.cms.gov

If you’re not sure if you are required to report for MIPS, enter your National Provider Identifier (NPI) in the MIPS Lookup Tool to find out whether you need to report. Additionally, if you know you are in a MIPS APM or Advanced APM, you can use the APM Lookup Tool.   

Questions about your participation status or MIPS data submission? Contact the Quality Payment Program Service Center by:

• Email: qpp@cms.hhs.gov
• Phone: 1-866-288-8292 (TTY: 1-877-715-6222) 

For more information and a quality reporting timeline, visit the Quality Payment Program website

Posted 2/8/18

FDA Approves Zytiga Plus Prednisone for Metastatic High-Risk Prostate Cancer

The Janssen Pharmaceutical Companies of Johnson & Johnson on February 8, 2018, announced U.S. Food and Drug Administration (FDA) approval of a new indication for Zytiga (abiraterone acetate) in combination with prednisone for the treatment of patients with metastatic high-risk castration-sensitive prostate cancer (CSPC). 

Read Corporate Press Release
Posted 2/8/18

ASCO Reviews Commercial Clinical Pathways Landscape

The American Society of Clinical Oncology (ASCO) reviews six leading commercial oncology pathway vendors in "Oncology Clinical Pathways: Charting the Landscape of Pathway Providers." The article, published online February 7, 2018, in the Journal of Oncology Practice," assesses six commercial clinical pathway vendors using ASCO's criteria for high-quality clinical pathways.

Read ASCO Press ReleaseAccess Article and Learn More
Posted 2/8/18

FDA Approves New Treatment for Certain Digestive Tract Cancers

On Jan. 26, 2018, the U.S. Food and Drug Administration (FDA) approved Lutathera (lutetium Lu 177 dotatate) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs), a type of cancer that affects the pancreas or gastrointestinal tract. This is the first time a radioactive drug, or radiopharmaceutical, has been approved for the treatment of GEP-NETs. Lutathera is indicated for adult patients with somatostatin receptor-positive GEP-NETs.

GEP-NETs can be present in the pancreas and in different parts of the gastrointestinal tract such as the stomach, intestines, colon and rectum. It is estimated that approximately one out of 27,000 people are diagnosed with GEP-NETs per year.

Read the FDA announcement.

Posted 1/26/2018

Alex Azar to Head HHS

On January 24, the U.S. Senate confirmed Alex Azar, as Secretary of the Department of Health and Human Services (HHS) by a 55-43 vote. Azar, a former Eli Lilly executive, is anticipated to align closely with Trump administration policies on the Affordable Care Act, Medicare spending, and other issues, reports Bloomberg BNA.

Posted 1/25/2018

CAP, IASLC, AMP Release Updated Lung Biomarker Guideline

The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) announced the much-anticipated release of their updated guideline for molecular testing and targeted therapies in lung cancer. The work of these three leading medical societies, updates their 2013 evidence-based guidelines.

Published first online on January 23, the “Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors,” makes revisions to standards for the molecular analysis of lung cancers for test results that reflect advances in understanding of lung cancer and the increase in available molecularly-targeted therapies.

“Several factors influenced this update, which builds on the guidance we set forth in 2013,” said Neal Lindeman, MD, director of Molecular Diagnostics at Brigham and Women’s Hospital and Associate Professor of Pathology at Harvard Medical School in Boston, and AMP member. “Clinical practice guidelines must continually assess new evidence as it accumulates and consider new testing technologies as they emerge,” he said in a statement.

According to the IASLC press release, the updated guideline "strengthens or reaffirms" the majority of recommendations included in the 2013 guideline and recommends testing for some new genes.

Read the updated guideline.

View resources from CAP, IASLC, and AMP to help pathologists and oncologists review and implement the guidelines (includes a summary of recommendations, teaching presention, and FAQs).

Posted 1/25/2018

MAC Operations To Continue During Government Shutdown

The Centers for Medicare & Medicaid Services (CMS) has stated that "During the time that the partial government shutdown is in effect, Medicare Administrative Contractors will continue to perform all functions related to Medicare fee-for-service claims processing and payment." This announcement was made through a special edition of CMS's MLN Connects dated Monday, January 22, 2018.

Posted 1/22/2018

MedPAC Recommends Eliminating MIPS

The Medicare Payment Advisory Commission (MedPAC) voted on Jan. 11, to recommend to Congress that the Merit-based Incentive Payment System (MIPS) be scrapped. The federal advisory panel suggested replacing the quality reporting program with a Voluntary Value Program. MedPAC is an independent congressional agency established by the Balanced Budget Act of 1997 to advise the U.S. Congress on issues affecting the Medicare program.

Whether Congress will accept MedPAC's recommendation to eliminate MIPS is unknown. However, Bloomberg BNA reports that a House Energy and Commerce Committee spokesperson has indicated that the committee plans to continue work to ensure the success of MIPS.

Posted 1/19/2018

FDA Approves Olaparib for Germline BRCA-mutated Metastatic Breast Cancer

On Jan. 12, 2018, the U.S. Food and Drug Administration (FDA) granted regular approval to olaparib tablets (Lynparza, AstraZeneca Pharmaceuticals LP), a poly (ADP-ribose) polymerase (PARP) inhibitor, for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting.

This is the first FDA-approved treatment for patients with gBRCAm HER2-negative metastatic breast cancer. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine treatment. Patients must be selected for therapy based on an FDA-approved companion diagnostic for olaparib.

Read the FDA announcement.

Posted 1/12/2018